Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

O2, repositorio institucional de la UOC
Publication Artículo científico (JournalArticle)

Multimodal analysis of the visual pathways in Friedreich’s ataxia reveals novel biomarkers

  • Thomas-Black, Gilbert
  • Altmann, Daniel
  • Crook, Harry
  • Solanky, Nita
  • Prados Carrasco, Ferran
  • Battiston, Marco
  • Grussu, Francesco
  • Yiannakas, Marios
  • Kanber, Baris
  • Jolly, Jasleen
  • Brett, Jon
  • Downes, Susan
  • Moran, Marni
  • Chan, Ping K.
  • Adewunmi, Emmanuel
  • Gandini Wheeler-Kingshott, Claudia A.M.
  • Németh, Andrea H.
  • Festenstien, Richard
  • Bremner, Fion
  • Giunti, Paola
Background. Optic neuropathy is a near ubiquitous feature of Friedreich's ataxia (FRDA). Previous studies have examined varying aspects of the anterior and posterior visual pathways but none so far have comprehensively evaluated the heterogeneity of degeneration across different areas of the retina, changes to the macula layers and combined these with volumetric MRI studies of the visual cortex and frataxin level. Methods. We investigated 62 genetically confirmed FRDA patients using an integrated approach as part of an observational cohort study. We included measurement of frataxin protein levels, clinical evaluation of visual and neurological function, optical coherence tomography to determine retinal nerve fibre layer thickness and macular layer volume and volumetric brain MRI. Results. We demonstrate that frataxin level correlates with peripapillary retinal nerve fibre layer thickness and that retinal sectors differ in their degree of degeneration. We also shown that retinal nerve fibre layer is thinner in FRDA patients than controls and that this thinning is influenced by the AAO and GAA1. Furthermore we show that the ganglion cell and inner plexiform layers are affected in FRDA. Our MRI data indicate that there are borderline correlations between retinal layers and areas of the cortex involved in visual processing. Conclusion. Our study demonstrates the uneven distribution of the axonopathy in the retinal nerve fibre layer and highlight the relative sparing of the papillomacular bundle and temporal sectors. We show that thinning of the retinal nerve fibre layer is associated with frataxin levels, supporting the use the two biomarkers in future clinical trials design. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset

  • Ricciardi, Antonio
  • Prados, Ferran
  • Yiannakas, Marios
  • Solanky, Bhavana
  • Grussu, Francesco
  • Kanber, Baris
MRI; Machine learning; Multiple sclerosis, Ressonància magnètica; Aprenentatge automàtic; Esclerosi múltiple, Resonancia magnética; Aprendizaje automático; Esclerosis múltiple, Introduction: Conventional MRI is routinely used for the characterization of pathological changes in multiple sclerosis (MS), but due to its lack of specificity is unable to provide accurate prognoses, explain disease heterogeneity and reconcile the gap between observed clinical symptoms and radiological evidence. Quantitative MRI provides measures of physiological abnormalities, otherwise invisible to conventional MRI, that correlate with MS severity. Analyzing quantitative MRI measures through machine learning techniques has been shown to improve the understanding of the underlying disease by better delineating its alteration patterns. Methods: In this retrospective study, a cohort of healthy controls (HC) and MS patients with different subtypes, followed up 15 years from clinically isolated syndrome (CIS), was analyzed to produce a multi-modal set of quantitative MRI features encompassing relaxometry, microstructure, sodium ion concentration, and tissue volumetry. Random forest classifiers were used to train a model able to discriminate between HC, CIS, relapsing remitting (RR) and secondary progressive (SP) MS patients based on these features and, for each classification task, to identify the relative contribution of each MRI-derived tissue property to the classification task itself. Results and discussion: Average classification accuracy scores of 99 and 95% were obtained when discriminating HC and CIS vs. SP, respectively; 82 and 83% for HC and CIS vs. RR; 76% for RR vs. SP, and 79% for HC vs. CIS. Different patterns of alterations were observed for each classification task, offering key insights in the understanding of MS phenotypes pathophysiology: atrophy and relaxometry emerged particularly in the classification of HC and CIS vs. MS, relaxometry within lesions in RR vs. SP, sodium ion concentration in HC vs. CIS, and microstructural alterations were involved across all tasks., This project has received funding under the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 634541. FG received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”. FG has also received support from the Beatriu de Pinós (2020 BP 00117) programme, funded by the Secretary of Universities and Research (Government of Catalonia). BK, FP, and OC are supported by the National Institute of Health Research Biomedical Research Centre at UCL and UCLH. EPSRC grants EP/M020533/1 and EP/J020990/01, MRC MR/T046422/1 and MR/T046473/1, Wellcome Trust award 221915/Z/20/Z, and the NIHR UCLH BRC support DCA's work in this area. CGWK also receives funding from Horizon 2020 [Research and Innovation Action Grants Human Brain Project 945539 (SGA3)], BRC (#BRC704/CAP/CGW), MRC (#MR/S026088/1), and Ataxia UK.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique

  • Tur Gomez, Carmen
  • De Angelis, Floriana
  • Prados, Ferran
  • Grussu, Francesco
  • Calvi, Alberto
  • Eshaghi, Arman
  • Kanber, Baris
Anisotropy; Lesion spatial distribution; Multiple sclerosis, Anisotropia; Distribució espacial de la lesió; Esclerosi múltiple, Anisotropía; Distribución espacial de la lesión; Esclerosis múltiple, Predicting disability in progressive multiple sclerosis (MS) is extremely challenging. Although there is some evidence that the spatial distribution of white matter (WM) lesions may play a role in disability accumulation, the lack of well-established quantitative metrics that characterise these aspects of MS pathology makes it difficult to assess their relevance for clinical progression. This study introduces a novel approach, called SPACE-MS, to quantitatively characterise spatial distributional features of brain MS lesions, so that these can be assessed as predictors of disability accumulation. In SPACE-MS, the covariance matrix of the spatial positions of each patient’s lesional voxels is computed and its eigenvalues extracted. These are combined to derive rotationally-invariant metrics known to be common and robust descriptors of ellipsoid shape such as anisotropy, planarity and sphericity. Additionally, SPACE-MS metrics include a neuraxis caudality index, which we defined for the whole-brain lesion mask as well as for the most caudal brain lesion. These indicate how distant from the supplementary motor cortex (along the neuraxis) the whole-brain mask or the most caudal brain lesions are. We applied SPACE-MS to data from 515 patients involved in three studies: the MS-SMART (NCT01910259) and MS-STAT1 (NCT00647348) secondary progressive MS trials, and an observational study of primary and secondary progressive MS. Patients were assessed on motor and cognitive disability scales and underwent structural brain MRI (1.5/3.0 T), at baseline and after 2 years. The MRI protocol included 3DT1-weighted (1x1x1mm3) and 2DT2-weighted (1x1x3mm3) anatomical imaging. WM lesions were semiautomatically segmented on the T2-weighted scans, deriving whole-brain lesion masks. After co-registering the masks to the T1 images, SPACE-MS metrics were calculated and analysed through a series of multiple linear regression models, which were built to assess the ability of spatial distributional metrics to explain concurrent and future disability after adjusting for confounders. Patients whose WM lesions laid more caudally along the neuraxis or were more isotropically distributed in the brain (i.e. with whole-brain lesion masks displaying a high sphericity index) at baseline had greater motor and/or cognitive disability at baseline and over time, independently of brain lesion load and atrophy measures. In conclusion, here we introduced the SPACE-MS approach, which we showed is able to capture clinically relevant spatial distributional features of MS lesions independently of the sheer amount of lesions and brain tissue loss. Location of lesions in lower parts of the brain, where neurite density is particularly high, such as in the cerebellum and brainstem, and greater spatial spreading of lesions (i.e. more isotropic whole-brain lesion masks), possibly reflecting a higher number of WM tracts involved, are associated with clinical deterioration in progressive MS. The usefulness of the SPACE-MS approach, here demonstrated in MS, may be explored in other conditions also characterised by the presence of brain WM lesions., Carmen Tur is currently being funded by a Junior Leader La Caixa Fellowship. The project that gave rise to these results received the support of a fellowship from ”la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/PI20/11760008. She has also received the 2021 Merck’s Award for the Investigation in MS, awarded by the Merck Foundation. In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She has also received honoraria from Roche and Novartis. Francesco Grussu has received funding under the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 634541, from the Engineering and Physical Sciences Research Council (EPSRC EP/R006032/1, M020533/1) and Rosetrees Trust (UK), and is now supported by PREdICT (a study funded by AstraZeneca in Spain). Ferran Prados was supported by the Guarantors of Brain and the National Institute for Health Research, University College London Hospitals Biomedical Research Centre. Rosa Cortese is supported by the ECTRIMS-MAGNIMS fellowships programme. Alberto Calvi is supported by ECTRIMS-MAGNIMS fellowship (2018), Guarantors of Brain “Entry” clinical fellowship (2019) and the UK MS Society PhD studentship (2020). Declan Chard is a consultant for Biogen and Hoffmann-La Roche. In the last 3 years, he has received research funding from the International Progressive MS Alliance, the UK MS Society, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre. Jeremy Chataway, in the last three years, has received support from the Efficacy and Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by the Canadian MS society. A local principal investigator for commercial trials funded by: Actelion, Biogen, Novartis and Roche; has received an investigator grant from Novartis; and has taken part in advisory boards/consultancy for Azadyne, Biogen, Celgene, Janssen, MedDay, Merck, Novartis and Roche. Alan J Thompson acknowledges grant support from the National Institute for Health Research HTA and BRC, and has received honoraria for consultancy from Eisai and Abbvie (paid to Institution), support for travel for consultancy from the International Progressive MS Alliance and National MS Society (USA), and receives an honorarium from SAGE Publishers as Editor-in-Chief of Multiple Sclerosis Journal. Olga Ciccarelli is supported by the National Institute for Health Research, University College London Hospitals Biomedical Research Centre. OC also receives research grant support from the MS Society of Great Britain and Northern Ireland, and the NIHR UCLH Biomedical Research Centre. She is an Associate Editor for Neurology, for which he receives an honorarium. Claudia A.M. Gandini Wheeler-Kingshott has received research grants (principal investigator and co-applicant) from the UK MS Society (#77), Wings for Life (#169111), BRC (#BRC704/CAP/CGW), UCL Global Challenges Research Fund (GCRF), MRC (#MR/S026088/1), Ataxia UK. CGWK is a shareholder in Queen Square Analytics Ltd.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comparison of Neurite Orientation Dispersion and Density Imaging and Two-Compartment Spherical Mean Technique Parameter Maps in Multiple Sclerosis

  • Johnson, Daniel
  • Ricciardi, Antonio
  • Prados, Ferran
  • Collorone, Sara
  • Brownlee, Wallace
  • Grussu, Francesco
  • Kanber, Baris
Microestructura; Esclerosi múltiple; Tècnica de mitjana esfèrica, Microestructura; Esclerosis múltiple; Técnica de la media esférica, Microstructure; Multiple sclerosis; Spherical mean technique, Background: Neurite orientation dispersion and density imaging (NODDI) and the spherical mean technique (SMT) are diffusion MRI methods providing metrics with sensitivity to similar characteristics of white matter microstructure. There has been limited comparison of changes in NODDI and SMT parameters due to multiple sclerosis (MS) pathology in clinical settings. Purpose: To compare group-wise differences between healthy controls and MS patients in NODDI and SMT metrics, investigating associations with disability and correlations with diffusion tensor imaging (DTI) metrics. Methods: Sixty three relapsing-remitting MS patients were compared to 28 healthy controls. NODDI and SMT metrics corresponding to intracellular volume fraction (vin), orientation dispersion (ODI and ODE), diffusivity (D) (SMT only) and isotropic volume fraction (viso) (NODDI only) were calculated from diffusion MRI data, alongside DTI metrics (fractional anisotropy, FA; axial/mean/radial diffusivity, AD/MD/RD). Correlations between all pairs of MRI metrics were calculated in normal-appearing white matter (NAWM). Associations with expanded disability status scale (EDSS), controlling for age and gender, were evaluated. Patient-control differences were assessed voxel-by-voxel in MNI space controlling for age and gender at the 5% significance level, correcting for multiple comparisons. Spatial overlap of areas showing significant differences were compared using Dice coefficients. Results: NODDI and SMT show significant associations with EDSS (standardised beta coefficient −0.34 in NAWM and −0.37 in lesions for NODDI vin; 0.38 and −0.31 for SMT ODE and vin in lesions; p < 0.05). Significant correlations in NAWM are observed between DTI and NODDI/SMT metrics. NODDI vin and SMT vin strongly correlated (r = 0.72, p < 0.05), likewise NODDI ODI and SMT ODE (r = −0.80, p < 0.05). All DTI, NODDI and SMT metrics detect widespread differences between patients and controls in NAWM (12.57% and 11.90% of MNI brain mask for SMT and NODDI vin, Dice overlap of 0.42). Data Conclusion: SMT and NODDI detect significant differences in white matter microstructure between MS patients and controls, concurring on the direction of these changes, providing consistent descriptors of tissue microstructure that correlate with disability and show alterations beyond focal damage. Our study suggests that NODDI and SMT may play a role in monitoring MS in clinical trials and practice., This study has received funding under the European Union's Horizon 2020 research and innovation programme under grant agreement No. 634541 (CDS-QuaMRI) and 666992. This study has also received support from the Engineering and Physical Sciences Research Council (EPSRC R006032/1, M020533/1, G007748, I027084, N018702), Spinal Research (UK), Wings for Life (Austria), Craig H. Neilsen Foundation (USA) for INSPIRED and UK Multiple Sclerosis Society (grants 892/08 and 77/2017). This study was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. FP was supported by a Guarantors of Brain post-doctoral non-clinical fellowship. AT was supported by an MRC grant (MR/S026088/1). EK was supported from the NIHR Great Ormond Street Hospital Biomedical Research Centre. FG was currently supported by the investigator-initiated PREdICT study at the Vall d'Hebron Institute of Oncology (Barcelona), funded by AstraZeneca and CRIS Cancer Foundation. AstraZeneca was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio

  • Boonsuth, Ratthaporn
  • Samson, Rebecca S.
  • Tur Gomez, Carmen
  • Battiston, Marco
  • Schneider, Torben
  • Grussu, Francesco
Neurografia de ressonància magnètica (MRN); Relació de transferència de magnetització (MTR); Esclerosi múltiple del sistema nerviós perifèric (SNP), Neurografía de resonancia magnética (MRN); Relación de transferencia de magnetización (MTR); Esclerosis múltiple del sistema nervioso periférico (SNP), Magnetic resonance neurography (MRN); Magnetisation transfer ratio (MTR); Multiple sclerosis peripheral nervous system (PNS), Background: Multiple sclerosis (MS) has traditionally been regarded as a disease confined to the central nervous system (CNS). However, neuropathological, electrophysiological, and imaging studies have demonstrated that the peripheral nervous system (PNS) is also involved, with demyelination and, to a lesser extent, axonal degeneration representing the main pathophysiological mechanisms. Aim: The purpose of this study was to assess PNS damage at the lumbar plexus and sciatic nerve anatomical locations in people with relapsing-remitting MS (RRMS) and healthy controls (HCs) in vivo using magnetisation transfer ratio (MTR), which is a known imaging biomarker sensitive to alterations in myelin content in neural tissue, and not previously explored in the context of PNS damage in MS. Method: Eleven HCs (7 female, mean age 33.6 years, range 24-50) and 15 people with RRMS (12 female, mean age 38.5 years, range 30-56) were recruited for this study and underwent magnetic resonance imaging (MRI) investigations together with clinical assessments using the expanded disability status scale (EDSS). Magnetic resonance neurography (MRN) was first used for visualisation and identification of the lumbar plexus and the sciatic nerve and MTR imaging was subsequently performed using identical scan geometry to MRN, enabling straightforward co-registration of all data to obtain global and regional mean MTR measurements. Linear regression models were used to identify differences in MTR values between HCs and people with RRMS and to identify an association between MTR measures and EDSS. Results: MTR values in the sciatic nerve of people with RRMS were found to be significantly lower compared to HCs, but no significant MTR changes were identified in the lumbar plexus of people with RRMS. The median EDSS in people with RRMS was 2.0 (range, 0-3). No relationship between the MTR measures in the PNS and EDSS were identified at any of the anatomical locations studied in this cohort of people with RRMS. Conclusion: The results from this study demonstrate the presence of PNS damage in people with RRMS and support the notion that these changes, suggestive of demyelination, maybe occurring independently at different anatomical locations within the PNS. Further investigations to confirm these findings and to clarify the pathophysiological basis of these alterations are warranted., The UK MS Society and the UCL-UCLH Biomedical Research Centre for ongoing support. CGW-K receives funding from the MS Society (#77), Wings for Life (#169111), BRC (#BRC704/CAP/CGW), UCL Global Challenges Research Fund (GCRF), MRC (#MR/S026088/1), Ataxia UK. FP had a non-clinical Postdoctoral Guarantors of Brain fellowship (2017-2020). FP was supported by the National Institute for Health Research, UCL Hospitals Biomedical Research Centre. CT is being funded by a Junior Leader La Caixa Fellowship (fellowship code is LCF/BQ/PI20/11760008), awarded by la Caixa Foundation (ID 100010434). She has also received the 2021 Merck's Award for the Investigation in MS, awarded by Fundación Merck Salud (Spain). In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She has also received honoraria from Roche and Novartis, and is a steering committee member of the O'HAND trial and of the Consensus group on Follow-on DMTs. This project has received funding under the European Union's Horizon 2020 research and innovation programme under grant agreement No. 634541 and from the Engineering and Physical Sciences Research Council (EPSRC EP/R006032/1), funding FG. FG was currently supported by PREdICT, a study at the Vall d'Hebron Institute of Oncology in Barcelona funded by AstraZeneca.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Feasibility of Data-Driven, Model-Free Quantitative MRI Protocol Design: Application to Brain and Prostate Diffusion-Relaxation Imaging

  • Blumberg, Stefano B.
  • Battiston, Marco
  • Kakkar, Lebina S.
  • Lin, Hongxiang
  • Grussu, Francesco
  • Ianus, Andrada
Brain; Protocol design; Quantitative MRI (qMRI), Cerebro; Diseño de protocolo; Resonancia magnética cuantitativa (qMRI), Cervell; Disseny del protocol; Ressonància magnètica quantitativa (qMRI), Purpose: We investigate the feasibility of data-driven, model-free quantitative MRI (qMRI) protocol design on in vivo brain and prostate diffusion-relaxation imaging (DRI). Methods: We select subsets of measurements within lengthy pilot scans, without identifying tissue parameters for which to optimise for. We use the “select and retrieve via direct upsampling” (SARDU-Net) algorithm, made of a selector, identifying measurement subsets, and a predictor, estimating fully-sampled signals from the subsets. We implement both using artificial neural networks, which are trained jointly end-to-end. We deploy the algorithm on brain (32 diffusion-/T1-weightings) and prostate (16 diffusion-/T2-weightings) DRI scans acquired on three healthy volunteers on two separate 3T Philips systems each. We used SARDU-Net to identify sub-protocols of fixed size, assessing reproducibility and testing sub-protocols for their potential to inform multi-contrast analyses via the T1-weighted spherical mean diffusion tensor (T1-SMDT, brain) and hybrid multi-dimensional MRI (HM-MRI, prostate) models, for which sub-protocol selection was not optimised explicitly. Results: In both brain and prostate, SARDU-Net identifies sub-protocols that maximise information content in a reproducible manner across training instantiations using a small number of pilot scans. The sub-protocols support T1-SMDT and HM-MRI multi-contrast modelling for which they were not optimised explicitly, providing signal quality-of-fit in the top 5% against extensive sub-protocol comparisons. Conclusions: Identifying economical but informative qMRI protocols from subsets of rich pilot scans is feasible and potentially useful in acquisition-time-sensitive applications in which there is not a qMRI model of choice. SARDU-Net is demonstrated to be a robust algorithm for data-driven, model-free protocol design., This project was funded by the Engineering and Physical Sciences Research Council (EPSRC EP/R006032/1, M020533/1, G007748, I027084, N018702). This project has received funding under the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 634541 and 666992, and from: Rosetrees Trust (United Kingdom, funding FG); Prostate Cancer United Kingdom Targeted Call 2014 (Translational Research St.2, project reference PG14-018-TR2); Cancer Research United Kingdom grant ref. A21099; Spinal Research (United Kingdom), Wings for Life (Austria), Craig H. Neilsen Foundation (United States) for jointly funding the INSPIRED study; Wings for Life (#169111); United Kingdom Multiple Sclerosis Society (grants 892/08 and 77/2017); the Department of Health’s National Institute for Health Research (NIHR) Biomedical Research Centres and UCLH NIHR Biomedical Research Centre; Champalimaud Centre for the Unknown, Lisbon (Portugal); European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 101003390. FG is currently supported by the investigator-initiated PREdICT study at the Vall d’Hebron Institute of Oncology (Barcelona), funded by AstraZeneca and CRIS Cancer Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers

  • Thomas-Black, Gilbert
  • Altmann, Daniel
  • Crook, Harry
  • Solanky, Nita
  • Battiston, Marco
  • Grussu, Francesco
  • Prados Carrasco, Ferran
Friedreich's ataxia; MRI; Biomarkers, Ataxia de Friedreich; Resonancia magnética; Biomarcadores, Atàxia de Friedreich; Ressonància magnètica; Biomarcadors, Background Optic neuropathy is a near ubiquitous feature of Friedreich's ataxia (FRDA). Previous studies have examined varying aspects of the anterior and posterior visual pathways but none so far have comprehensively evaluated the heterogeneity of degeneration across different areas of the retina, changes to the macula layers and combined these with volumetric MRI studies of the visual cortex and frataxin level. Methods We investigated 62 genetically confirmed FRDA patients using an integrated approach as part of an observational cohort study. We included measurement of frataxin protein levels, clinical evaluation of visual and neurological function, optical coherence tomography to determine retinal nerve fibre layer thickness and macular layer volume and volumetric brain MRI. Results We demonstrate that frataxin level correlates with peripapillary retinal nerve fibre layer thickness and that retinal sectors differ in their degree of degeneration. We also shown that retinal nerve fibre layer is thinner in FRDA patients than controls and that this thinning is influenced by the AAO and GAA1. Furthermore we show that the ganglion cell and inner plexiform layers are affected in FRDA. Our MRI data indicate that there are borderline correlations between retinal layers and areas of the cortex involved in visual processing. Conclusion Our study demonstrates the uneven distribution of the axonopathy in the retinal nerve fibre layer and highlight the relative sparing of the papillomacular bundle and temporal sectors. We show that thinning of the retinal nerve fibre layer is associated with frataxin levels, supporting the use the two biomarkers in future clinical trials design. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., This project has received funding under the European Union's Horizon 2020 research and innovation programme under grant agreement No. 634541, from the Engineering and Physical Sciences Research Council (EPSRC EP/R006032/1, M020533/1, G007748, I027084, N018702) and from Rosetrees Trust (UK), which supported FG. FG is currently supported by the investigator-initiated PREdICT study at the Vall d'Hebron Institute of Oncology (Barcelona), funded by AstraZeneca and CRIS Cancer Foundation. Funding support from Spinal Research (UK), Wings for Life (Austria), Craig H. Neilsen Foundation (USA) for jointly funding the INSPIRED study, Wings for Life (#169111), UK Multiple Sclerosis Society (grants 892/08 and 77/2017), Department of Health's National Institute for Health Research (NIHR) Biomedical Research Centres and UCLH NIHR Biomedical Research Centre is also acknowledged. FP is funded by NIHR University College London Hospitals Biomedical Research Council. Claudia A. M. Gandini Wheeler-Kingshott (CGWK) received funding from the MS Society (#77), Wings for Life (#169111), Horizon2020 (Human Brain Project), BRC (#BRC704/CAP/CGW), MRC (#MR/S026088/1), Ataxia UK. CGWK is a shareholder in Queen Square Analytics Ltd. No other authors have any financial disclosures to declare. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The sponsor and funding organisation had no role in the design or conduct of this research.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Deep gray matter volume loss drives disability worsening in multiple sclerosis

  • Eshaghi, Arman|||0000-0002-6652-3512
  • Prados Carrasco, Ferran|||0000-0002-7872-0142
  • Brownlee, Wallace J.|||0000-0003-0481-8902
  • Altmann, Daniel R.
  • Tur, Carmen|||0000-0003-1849-3184
  • Cardoso, M. Jorge
  • De Angelis, Floriana
  • van de Pavert, Steven H.
  • Cawley, Niamh
  • De Stefano, Nicola|||0000-0003-4930-7639
  • Stromillo, M. Laura
  • Battaglini, Marco|||0000-0002-9188-4408
  • Ruggieri, Serena|||0000-0001-5287-3290
  • Gasperini, Claudio|||0000-0002-3959-4067
  • Filippi, Massimo|||0000-0002-5485-0479
  • Rocca, Maria A.|||0000-0003-2358-4320
  • Rovira, Alex|||0000-0002-2132-6750
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Vrenken, Hugo|||0000-0001-9106-1172
  • Leurs, Cyra E.
  • Killestein, Joep
  • Pirpamer, Lukas
  • Enzinger, Christian|||0000-0001-9764-7617
  • Ourselin, Sebastien|||0000-0002-5694-5340
  • Wheeler-Kingshott, Claudia A. M. Gandini
  • Chard, Declan|||0000-0003-3076-2682
  • Thompson, Alan J.
  • Alexander, Daniel C.|||0000-0003-2439-350X
  • Barkhof, Frederik|||0000-0003-3543-3706
  • Ciccarelli, Olga|||0000-0001-7485-1367
Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation in MS. We analyzed 3,604 brain high-resolution T1-weighted magnetic resonance imaging scans from 1,417 participants: 1,214 MS patients (253 clinically isolated syndrome [CIS], 708 relapsing-remitting [RRMS], 128 secondary-progressive [SPMS], and 125 primary-progressive [PPMS]), over an average follow-up of 2.41 years (standard deviation [SD] = 1.97), and 203 healthy controls (HCs; average follow-up = 1.83 year; SD = 1.77), attending seven European centers. Disability was assessed with the Expanded Disability Status Scale (EDSS). We obtained volumes of the deep GM (DGM), temporal, frontal, parietal, occipital and cerebellar GM, brainstem, and cerebral white matter. Hierarchical mixed models assessed annual percentage rate of regional tissue loss and identified regional volumes associated with time-to-EDSS progression. SPMS showed the lowest baseline volumes of cortical GM and DGM. Of all baseline regional volumes, only that of the DGM predicted time-to-EDSS progression (hazard ratio = 0.73; 95% confidence interval, 0.65, 0.82; p < 0.001): for every standard deviation decrease in baseline DGM volume, the risk of presenting a shorter time to EDSS worsening during follow-up increased by 27%. Of all longitudinal measures, DGM showed the fastest annual rate of atrophy, which was faster in SPMS (-1.45%), PPMS (-1.66%), and RRMS (-1.34%) than CIS (-0.88%) and HCs (-0.94%; p < 0.01). The rate of temporal GM atrophy in SPMS (-1.21%) was significantly faster than RRMS (-0.76%), CIS (-0.75%), and HCs (-0.51%). Similarly, the rate of parietal GM atrophy in SPMS (-1.24-%) was faster than CIS (-0.63%) and HCs (-0.23%; all p values <0.05). Only the atrophy rate in DGM in patients was significantly associated with disability accumulation (beta = 0.04; p < 0.001). This large, multicenter and longitudinal study shows that DGM volume loss drives disability accumulation in MS, and that temporal cortical GM shows accelerated atrophy in SPMS than RRMS. The difference in regional GM atrophy development between phenotypes needs to be taken into account when evaluating treatment effect of therapeutic interventions. Ann Neurol 2018;83:210-222.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Progression of regional grey matter atrophy in multiple sclerosis

  • Eshaghi, Arman|||0000-0002-6652-3512
  • Marinescu, Razvan V.
  • Young, Alexandra L.
  • Firth, Nicholas C.
  • Prados Carrasco, Ferran|||0000-0002-7872-0142
  • Jorge Cardoso, M.
  • Tur, Carmen|||0000-0003-1849-3184
  • De Angelis, Floriana
  • Cawley, Niamh
  • Brownlee, Wallace J.|||0000-0003-0481-8902
  • De Stefano, Nicola|||0000-0003-4930-7639
  • Laura Stromillo, M.
  • Battaglini, Marco|||0000-0002-9188-4408
  • Ruggieri, Serena|||0000-0001-5287-3290
  • Gasperini, Claudio|||0000-0002-3959-4067
  • Filippi, Massimo|||0000-0002-5485-0479
  • Rocca, Maria A.|||0000-0003-2358-4320
  • Rovira, Alex|||0000-0002-2132-6750
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Geurts, Jeroen J. G.
  • Vrenken, Hugo|||0000-0001-9106-1172
  • Wottschel, Viktor|||0000-0002-2902-2268
  • Leurs, Cyra E.
  • Uitdehaag, Bernard
  • Pirpamer, Lukas
  • Enzinger, Christian|||0000-0001-9764-7617
  • Ourselin, Sebastien|||0000-0002-5694-5340
  • Gandini Wheeler-Kingshott, Claudia A. M.
  • Chard, Declan|||0000-0003-3076-2682
  • Thompson, Alan J.
  • Barkhof, Frederik|||0000-0003-3543-3706
  • Alexander, Daniel C.|||0000-0003-2439-350X
  • Ciccarelli, Olga|||0000-0001-7485-1367
See Stankoff and Louapre (doi:) for a scientific commentary on this article. Grey matter atrophy in multiple sclerosis affects certain areas preferentially. Eshaghi et al. use a data-driven computational model to predict the order in which regions atrophy, and use this sequence to stage patients. Atrophy begins in deep grey matter nuclei and posterior cortical regions, before spreading to other cortical areas. See Stankoff and Louapre (doi:) for a scientific commentary on this article. Grey matter atrophy is present from the earliest stages of multiple sclerosis, but its temporal ordering is poorly understood. We aimed to determine the sequence in which grey matter regions become atrophic in multiple sclerosis and its association with disability accumulation. In this longitudinal study, we included 1417 subjects: 253 with clinically isolated syndrome, 708 with relapsing-remitting multiple sclerosis, 128 with secondary-progressive multiple sclerosis, 125 with primary-progressive multiple sclerosis, and 203 healthy control subjects from seven European centres. Subjects underwent repeated MRI (total number of scans 3604); the mean follow-up for patients was 2.41 years (standard deviation = 1.97). Disability was scored using the Expanded Disability Status Scale. We calculated the volume of brain grey matter regions and brainstem using an unbiased within-subject template and used an established data-driven event-based model to determine the sequence of occurrence of atrophy and its uncertainty. We assigned each subject to a specific event-based model stage, based on the number of their atrophic regions. Linear mixed-effects models were used to explore associations between the rate of increase in event-based model stages, and T lesion load, disease-modifying treatments, comorbidity, disease duration and disability accumulation. The first regions to become atrophic in patients with clinically isolated syndrome and relapse-onset multiple sclerosis were the posterior cingulate cortex and precuneus, followed by the middle cingulate cortex, brainstem and thalamus. A similar sequence of atrophy was detected in primary-progressive multiple sclerosis with the involvement of the thalamus, cuneus, precuneus, and pallidum, followed by the brainstem and posterior cingulate cortex. The cerebellum, caudate and putamen showed early atrophy in relapse-onset multiple sclerosis and late atrophy in primary-progressive multiple sclerosis. Patients with secondary-progressive multiple sclerosis showed the highest event-based model stage (the highest number of atrophic regions, P < 0.001) at the study entry. All multiple sclerosis phenotypes, but clinically isolated syndrome, showed a faster rate of increase in the event-based model stage than healthy controls. T lesion load and disease duration in all patients were associated with increased event-based model stage, but no effects of disease-modifying treatments and comorbidity on event-based model stage were observed. The annualized rate of event-based model stage was associated with the disability accumulation in relapsing-remitting multiple sclerosis, independent of disease duration (P < 0.0001). The data-driven staging of atrophy progression in a large multiple sclerosis sample demonstrates that grey matter atrophy spreads to involve more regions over time. The sequence in which regions become atrophic is reasonably consistent across multiple sclerosis phenotypes. The spread of atrophy was associated with disease duration and with disability accumulation over time in relapsing-remitting multiple sclerosis.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset

  • Ricciardi, Antonio
  • Prados, Ferran
  • Yiannakas, Marios
  • Solanky, Bhavana
  • Grussu, Francesco
  • Kanber, Baris
MRI; Machine learning; Multiple sclerosis, Ressonància magnètica; Aprenentatge automàtic; Esclerosi múltiple, Resonancia magnética; Aprendizaje automático; Esclerosis múltiple, Introduction: Conventional MRI is routinely used for the characterization of pathological changes in multiple sclerosis (MS), but due to its lack of specificity is unable to provide accurate prognoses, explain disease heterogeneity and reconcile the gap between observed clinical symptoms and radiological evidence. Quantitative MRI provides measures of physiological abnormalities, otherwise invisible to conventional MRI, that correlate with MS severity. Analyzing quantitative MRI measures through machine learning techniques has been shown to improve the understanding of the underlying disease by better delineating its alteration patterns. Methods: In this retrospective study, a cohort of healthy controls (HC) and MS patients with different subtypes, followed up 15 years from clinically isolated syndrome (CIS), was analyzed to produce a multi-modal set of quantitative MRI features encompassing relaxometry, microstructure, sodium ion concentration, and tissue volumetry. Random forest classifiers were used to train a model able to discriminate between HC, CIS, relapsing remitting (RR) and secondary progressive (SP) MS patients based on these features and, for each classification task, to identify the relative contribution of each MRI-derived tissue property to the classification task itself. Results and discussion: Average classification accuracy scores of 99 and 95% were obtained when discriminating HC and CIS vs. SP, respectively; 82 and 83% for HC and CIS vs. RR; 76% for RR vs. SP, and 79% for HC vs. CIS. Different patterns of alterations were observed for each classification task, offering key insights in the understanding of MS phenotypes pathophysiology: atrophy and relaxometry emerged particularly in the classification of HC and CIS vs. MS, relaxometry within lesions in RR vs. SP, sodium ion concentration in HC vs. CIS, and microstructural alterations were involved across all tasks., This project has received funding under the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 634541. FG received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”. FG has also received support from the Beatriu de Pinós (2020 BP 00117) programme, funded by the Secretary of Universities and Research (Government of Catalonia). BK, FP, and OC are supported by the National Institute of Health Research Biomedical Research Centre at UCL and UCLH. EPSRC grants EP/M020533/1 and EP/J020990/01, MRC MR/T046422/1 and MR/T046473/1, Wellcome Trust award 221915/Z/20/Z, and the NIHR UCLH BRC support DCA's work in this area. CGWK also receives funding from Horizon 2020 [Research and Innovation Action Grants Human Brain Project 945539 (SGA3)], BRC (#BRC704/CAP/CGW), MRC (#MR/S026088/1), and Ataxia UK.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio

  • Boonsuth, Ratthaporn
  • Samson, Rebecca S.
  • Tur Gomez, Carmen
  • Battiston, Marco
  • Schneider, Torben
  • Grussu, Francesco
Neurografia de ressonància magnètica (MRN); Relació de transferència de magnetització (MTR); Esclerosi múltiple del sistema nerviós perifèric (SNP), Neurografía de resonancia magnética (MRN); Relación de transferencia de magnetización (MTR); Esclerosis múltiple del sistema nervioso periférico (SNP), Magnetic resonance neurography (MRN); Magnetisation transfer ratio (MTR); Multiple sclerosis peripheral nervous system (PNS), Background: Multiple sclerosis (MS) has traditionally been regarded as a disease confined to the central nervous system (CNS). However, neuropathological, electrophysiological, and imaging studies have demonstrated that the peripheral nervous system (PNS) is also involved, with demyelination and, to a lesser extent, axonal degeneration representing the main pathophysiological mechanisms. Aim: The purpose of this study was to assess PNS damage at the lumbar plexus and sciatic nerve anatomical locations in people with relapsing-remitting MS (RRMS) and healthy controls (HCs) in vivo using magnetisation transfer ratio (MTR), which is a known imaging biomarker sensitive to alterations in myelin content in neural tissue, and not previously explored in the context of PNS damage in MS. Method: Eleven HCs (7 female, mean age 33.6 years, range 24-50) and 15 people with RRMS (12 female, mean age 38.5 years, range 30-56) were recruited for this study and underwent magnetic resonance imaging (MRI) investigations together with clinical assessments using the expanded disability status scale (EDSS). Magnetic resonance neurography (MRN) was first used for visualisation and identification of the lumbar plexus and the sciatic nerve and MTR imaging was subsequently performed using identical scan geometry to MRN, enabling straightforward co-registration of all data to obtain global and regional mean MTR measurements. Linear regression models were used to identify differences in MTR values between HCs and people with RRMS and to identify an association between MTR measures and EDSS. Results: MTR values in the sciatic nerve of people with RRMS were found to be significantly lower compared to HCs, but no significant MTR changes were identified in the lumbar plexus of people with RRMS. The median EDSS in people with RRMS was 2.0 (range, 0-3). No relationship between the MTR measures in the PNS and EDSS were identified at any of the anatomical locations studied in this cohort of people with RRMS. Conclusion: The results from this study demonstrate the presence of PNS damage in people with RRMS and support the notion that these changes, suggestive of demyelination, maybe occurring independently at different anatomical locations within the PNS. Further investigations to confirm these findings and to clarify the pathophysiological basis of these alterations are warranted., The UK MS Society and the UCL-UCLH Biomedical Research Centre for ongoing support. CGW-K receives funding from the MS Society (#77), Wings for Life (#169111), BRC (#BRC704/CAP/CGW), UCL Global Challenges Research Fund (GCRF), MRC (#MR/S026088/1), Ataxia UK. FP had a non-clinical Postdoctoral Guarantors of Brain fellowship (2017-2020). FP was supported by the National Institute for Health Research, UCL Hospitals Biomedical Research Centre. CT is being funded by a Junior Leader La Caixa Fellowship (fellowship code is LCF/BQ/PI20/11760008), awarded by la Caixa Foundation (ID 100010434). She has also received the 2021 Merck's Award for the Investigation in MS, awarded by Fundación Merck Salud (Spain). In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She has also received honoraria from Roche and Novartis, and is a steering committee member of the O'HAND trial and of the Consensus group on Follow-on DMTs. This project has received funding under the European Union's Horizon 2020 research and innovation programme under grant agreement No. 634541 and from the Engineering and Physical Sciences Research Council (EPSRC EP/R006032/1), funding FG. FG was currently supported by PREdICT, a study at the Vall d'Hebron Institute of Oncology in Barcelona funded by AstraZeneca.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Feasibility of Data-Driven, Model-Free Quantitative MRI Protocol Design: Application to Brain and Prostate Diffusion-Relaxation Imaging

  • Blumberg, Stefano B.
  • Battiston, Marco
  • Kakkar, Lebina S.
  • Lin, Hongxiang
  • Grussu, Francesco
  • Ianus, Andrada
Brain; Protocol design; Quantitative MRI (qMRI), Cerebro; Diseño de protocolo; Resonancia magnética cuantitativa (qMRI), Cervell; Disseny del protocol; Ressonància magnètica quantitativa (qMRI), Purpose: We investigate the feasibility of data-driven, model-free quantitative MRI (qMRI) protocol design on in vivo brain and prostate diffusion-relaxation imaging (DRI). Methods: We select subsets of measurements within lengthy pilot scans, without identifying tissue parameters for which to optimise for. We use the “select and retrieve via direct upsampling” (SARDU-Net) algorithm, made of a selector, identifying measurement subsets, and a predictor, estimating fully-sampled signals from the subsets. We implement both using artificial neural networks, which are trained jointly end-to-end. We deploy the algorithm on brain (32 diffusion-/T1-weightings) and prostate (16 diffusion-/T2-weightings) DRI scans acquired on three healthy volunteers on two separate 3T Philips systems each. We used SARDU-Net to identify sub-protocols of fixed size, assessing reproducibility and testing sub-protocols for their potential to inform multi-contrast analyses via the T1-weighted spherical mean diffusion tensor (T1-SMDT, brain) and hybrid multi-dimensional MRI (HM-MRI, prostate) models, for which sub-protocol selection was not optimised explicitly. Results: In both brain and prostate, SARDU-Net identifies sub-protocols that maximise information content in a reproducible manner across training instantiations using a small number of pilot scans. The sub-protocols support T1-SMDT and HM-MRI multi-contrast modelling for which they were not optimised explicitly, providing signal quality-of-fit in the top 5% against extensive sub-protocol comparisons. Conclusions: Identifying economical but informative qMRI protocols from subsets of rich pilot scans is feasible and potentially useful in acquisition-time-sensitive applications in which there is not a qMRI model of choice. SARDU-Net is demonstrated to be a robust algorithm for data-driven, model-free protocol design., This project was funded by the Engineering and Physical Sciences Research Council (EPSRC EP/R006032/1, M020533/1, G007748, I027084, N018702). This project has received funding under the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 634541 and 666992, and from: Rosetrees Trust (United Kingdom, funding FG); Prostate Cancer United Kingdom Targeted Call 2014 (Translational Research St.2, project reference PG14-018-TR2); Cancer Research United Kingdom grant ref. A21099; Spinal Research (United Kingdom), Wings for Life (Austria), Craig H. Neilsen Foundation (United States) for jointly funding the INSPIRED study; Wings for Life (#169111); United Kingdom Multiple Sclerosis Society (grants 892/08 and 77/2017); the Department of Health’s National Institute for Health Research (NIHR) Biomedical Research Centres and UCLH NIHR Biomedical Research Centre; Champalimaud Centre for the Unknown, Lisbon (Portugal); European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 101003390. FG is currently supported by the investigator-initiated PREdICT study at the Vall d’Hebron Institute of Oncology (Barcelona), funded by AstraZeneca and CRIS Cancer Foundation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique

  • Tur Gomez, Carmen
  • De Angelis, Floriana
  • Prados, Ferran
  • Grussu, Francesco
  • Calvi, Alberto
  • Eshaghi, Arman
  • Kanber, Baris
Anisotropy; Lesion spatial distribution; Multiple sclerosis, Anisotropia; Distribució espacial de la lesió; Esclerosi múltiple, Anisotropía; Distribución espacial de la lesión; Esclerosis múltiple, Predicting disability in progressive multiple sclerosis (MS) is extremely challenging. Although there is some evidence that the spatial distribution of white matter (WM) lesions may play a role in disability accumulation, the lack of well-established quantitative metrics that characterise these aspects of MS pathology makes it difficult to assess their relevance for clinical progression. This study introduces a novel approach, called SPACE-MS, to quantitatively characterise spatial distributional features of brain MS lesions, so that these can be assessed as predictors of disability accumulation. In SPACE-MS, the covariance matrix of the spatial positions of each patient’s lesional voxels is computed and its eigenvalues extracted. These are combined to derive rotationally-invariant metrics known to be common and robust descriptors of ellipsoid shape such as anisotropy, planarity and sphericity. Additionally, SPACE-MS metrics include a neuraxis caudality index, which we defined for the whole-brain lesion mask as well as for the most caudal brain lesion. These indicate how distant from the supplementary motor cortex (along the neuraxis) the whole-brain mask or the most caudal brain lesions are. We applied SPACE-MS to data from 515 patients involved in three studies: the MS-SMART (NCT01910259) and MS-STAT1 (NCT00647348) secondary progressive MS trials, and an observational study of primary and secondary progressive MS. Patients were assessed on motor and cognitive disability scales and underwent structural brain MRI (1.5/3.0 T), at baseline and after 2 years. The MRI protocol included 3DT1-weighted (1x1x1mm3) and 2DT2-weighted (1x1x3mm3) anatomical imaging. WM lesions were semiautomatically segmented on the T2-weighted scans, deriving whole-brain lesion masks. After co-registering the masks to the T1 images, SPACE-MS metrics were calculated and analysed through a series of multiple linear regression models, which were built to assess the ability of spatial distributional metrics to explain concurrent and future disability after adjusting for confounders. Patients whose WM lesions laid more caudally along the neuraxis or were more isotropically distributed in the brain (i.e. with whole-brain lesion masks displaying a high sphericity index) at baseline had greater motor and/or cognitive disability at baseline and over time, independently of brain lesion load and atrophy measures. In conclusion, here we introduced the SPACE-MS approach, which we showed is able to capture clinically relevant spatial distributional features of MS lesions independently of the sheer amount of lesions and brain tissue loss. Location of lesions in lower parts of the brain, where neurite density is particularly high, such as in the cerebellum and brainstem, and greater spatial spreading of lesions (i.e. more isotropic whole-brain lesion masks), possibly reflecting a higher number of WM tracts involved, are associated with clinical deterioration in progressive MS. The usefulness of the SPACE-MS approach, here demonstrated in MS, may be explored in other conditions also characterised by the presence of brain WM lesions., Carmen Tur is currently being funded by a Junior Leader La Caixa Fellowship. The project that gave rise to these results received the support of a fellowship from ”la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/PI20/11760008. She has also received the 2021 Merck’s Award for the Investigation in MS, awarded by the Merck Foundation. In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She has also received honoraria from Roche and Novartis. Francesco Grussu has received funding under the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 634541, from the Engineering and Physical Sciences Research Council (EPSRC EP/R006032/1, M020533/1) and Rosetrees Trust (UK), and is now supported by PREdICT (a study funded by AstraZeneca in Spain). Ferran Prados was supported by the Guarantors of Brain and the National Institute for Health Research, University College London Hospitals Biomedical Research Centre. Rosa Cortese is supported by the ECTRIMS-MAGNIMS fellowships programme. Alberto Calvi is supported by ECTRIMS-MAGNIMS fellowship (2018), Guarantors of Brain “Entry” clinical fellowship (2019) and the UK MS Society PhD studentship (2020). Declan Chard is a consultant for Biogen and Hoffmann-La Roche. In the last 3 years, he has received research funding from the International Progressive MS Alliance, the UK MS Society, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre. Jeremy Chataway, in the last three years, has received support from the Efficacy and Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by the Canadian MS society. A local principal investigator for commercial trials funded by: Actelion, Biogen, Novartis and Roche; has received an investigator grant from Novartis; and has taken part in advisory boards/consultancy for Azadyne, Biogen, Celgene, Janssen, MedDay, Merck, Novartis and Roche. Alan J Thompson acknowledges grant support from the National Institute for Health Research HTA and BRC, and has received honoraria for consultancy from Eisai and Abbvie (paid to Institution), support for travel for consultancy from the International Progressive MS Alliance and National MS Society (USA), and receives an honorarium from SAGE Publishers as Editor-in-Chief of Multiple Sclerosis Journal. Olga Ciccarelli is supported by the National Institute for Health Research, University College London Hospitals Biomedical Research Centre. OC also receives research grant support from the MS Society of Great Britain and Northern Ireland, and the NIHR UCLH Biomedical Research Centre. She is an Associate Editor for Neurology, for which he receives an honorarium. Claudia A.M. Gandini Wheeler-Kingshott has received research grants (principal investigator and co-applicant) from the UK MS Society (#77), Wings for Life (#169111), BRC (#BRC704/CAP/CGW), UCL Global Challenges Research Fund (GCRF), MRC (#MR/S026088/1), Ataxia UK. CGWK is a shareholder in Queen Square Analytics Ltd.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Comparison of Neurite Orientation Dispersion and Density Imaging and Two-Compartment Spherical Mean Technique Parameter Maps in Multiple Sclerosis

  • Johnson, Daniel
  • Ricciardi, Antonio
  • Prados, Ferran
  • Collorone, Sara
  • Brownlee, Wallace
  • Grussu, Francesco
  • Kanber, Baris
Microestructura; Esclerosi múltiple; Tècnica de mitjana esfèrica, Microestructura; Esclerosis múltiple; Técnica de la media esférica, Microstructure; Multiple sclerosis; Spherical mean technique, Background: Neurite orientation dispersion and density imaging (NODDI) and the spherical mean technique (SMT) are diffusion MRI methods providing metrics with sensitivity to similar characteristics of white matter microstructure. There has been limited comparison of changes in NODDI and SMT parameters due to multiple sclerosis (MS) pathology in clinical settings. Purpose: To compare group-wise differences between healthy controls and MS patients in NODDI and SMT metrics, investigating associations with disability and correlations with diffusion tensor imaging (DTI) metrics. Methods: Sixty three relapsing-remitting MS patients were compared to 28 healthy controls. NODDI and SMT metrics corresponding to intracellular volume fraction (vin), orientation dispersion (ODI and ODE), diffusivity (D) (SMT only) and isotropic volume fraction (viso) (NODDI only) were calculated from diffusion MRI data, alongside DTI metrics (fractional anisotropy, FA; axial/mean/radial diffusivity, AD/MD/RD). Correlations between all pairs of MRI metrics were calculated in normal-appearing white matter (NAWM). Associations with expanded disability status scale (EDSS), controlling for age and gender, were evaluated. Patient-control differences were assessed voxel-by-voxel in MNI space controlling for age and gender at the 5% significance level, correcting for multiple comparisons. Spatial overlap of areas showing significant differences were compared using Dice coefficients. Results: NODDI and SMT show significant associations with EDSS (standardised beta coefficient −0.34 in NAWM and −0.37 in lesions for NODDI vin; 0.38 and −0.31 for SMT ODE and vin in lesions; p < 0.05). Significant correlations in NAWM are observed between DTI and NODDI/SMT metrics. NODDI vin and SMT vin strongly correlated (r = 0.72, p < 0.05), likewise NODDI ODI and SMT ODE (r = −0.80, p < 0.05). All DTI, NODDI and SMT metrics detect widespread differences between patients and controls in NAWM (12.57% and 11.90% of MNI brain mask for SMT and NODDI vin, Dice overlap of 0.42). Data Conclusion: SMT and NODDI detect significant differences in white matter microstructure between MS patients and controls, concurring on the direction of these changes, providing consistent descriptors of tissue microstructure that correlate with disability and show alterations beyond focal damage. Our study suggests that NODDI and SMT may play a role in monitoring MS in clinical trials and practice., This study has received funding under the European Union's Horizon 2020 research and innovation programme under grant agreement No. 634541 (CDS-QuaMRI) and 666992. This study has also received support from the Engineering and Physical Sciences Research Council (EPSRC R006032/1, M020533/1, G007748, I027084, N018702), Spinal Research (UK), Wings for Life (Austria), Craig H. Neilsen Foundation (USA) for INSPIRED and UK Multiple Sclerosis Society (grants 892/08 and 77/2017). This study was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. FP was supported by a Guarantors of Brain post-doctoral non-clinical fellowship. AT was supported by an MRC grant (MR/S026088/1). EK was supported from the NIHR Great Ormond Street Hospital Biomedical Research Centre. FG was currently supported by the investigator-initiated PREdICT study at the Vall d'Hebron Institute of Oncology (Barcelona), funded by AstraZeneca and CRIS Cancer Foundation. AstraZeneca was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers

  • Thomas-Black, Gilbert
  • Altmann, Daniel
  • Crook, Harry
  • Solanky, Nita
  • Battiston, Marco
  • Grussu, Francesco
  • Prados Carrasco, Ferran
Friedreich's ataxia; MRI; Biomarkers, Ataxia de Friedreich; Resonancia magnética; Biomarcadores, Atàxia de Friedreich; Ressonància magnètica; Biomarcadors, Background Optic neuropathy is a near ubiquitous feature of Friedreich's ataxia (FRDA). Previous studies have examined varying aspects of the anterior and posterior visual pathways but none so far have comprehensively evaluated the heterogeneity of degeneration across different areas of the retina, changes to the macula layers and combined these with volumetric MRI studies of the visual cortex and frataxin level. Methods We investigated 62 genetically confirmed FRDA patients using an integrated approach as part of an observational cohort study. We included measurement of frataxin protein levels, clinical evaluation of visual and neurological function, optical coherence tomography to determine retinal nerve fibre layer thickness and macular layer volume and volumetric brain MRI. Results We demonstrate that frataxin level correlates with peripapillary retinal nerve fibre layer thickness and that retinal sectors differ in their degree of degeneration. We also shown that retinal nerve fibre layer is thinner in FRDA patients than controls and that this thinning is influenced by the AAO and GAA1. Furthermore we show that the ganglion cell and inner plexiform layers are affected in FRDA. Our MRI data indicate that there are borderline correlations between retinal layers and areas of the cortex involved in visual processing. Conclusion Our study demonstrates the uneven distribution of the axonopathy in the retinal nerve fibre layer and highlight the relative sparing of the papillomacular bundle and temporal sectors. We show that thinning of the retinal nerve fibre layer is associated with frataxin levels, supporting the use the two biomarkers in future clinical trials design. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., This project has received funding under the European Union's Horizon 2020 research and innovation programme under grant agreement No. 634541, from the Engineering and Physical Sciences Research Council (EPSRC EP/R006032/1, M020533/1, G007748, I027084, N018702) and from Rosetrees Trust (UK), which supported FG. FG is currently supported by the investigator-initiated PREdICT study at the Vall d'Hebron Institute of Oncology (Barcelona), funded by AstraZeneca and CRIS Cancer Foundation. Funding support from Spinal Research (UK), Wings for Life (Austria), Craig H. Neilsen Foundation (USA) for jointly funding the INSPIRED study, Wings for Life (#169111), UK Multiple Sclerosis Society (grants 892/08 and 77/2017), Department of Health's National Institute for Health Research (NIHR) Biomedical Research Centres and UCLH NIHR Biomedical Research Centre is also acknowledged. FP is funded by NIHR University College London Hospitals Biomedical Research Council. Claudia A. M. Gandini Wheeler-Kingshott (CGWK) received funding from the MS Society (#77), Wings for Life (#169111), Horizon2020 (Human Brain Project), BRC (#BRC704/CAP/CGW), MRC (#MR/S026088/1), Ataxia UK. CGWK is a shareholder in Queen Square Analytics Ltd. No other authors have any financial disclosures to declare. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The sponsor and funding organisation had no role in the design or conduct of this research.